This brand name is authorized in Estonia, Finland, Japan, United Kingdom, United States
The drug ZANOSAR contains one active pharmaceutical ingredient (API):
|
1
Streptozocin
UNII 5W494URQ81 - STREPTOZOCIN
|
|
|
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZANOSAR Powder for concentrate for solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01AD04 | Streptozocin | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AD Nitrosoureas |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1778250, 1778531 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 399347 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 356918 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4219406D1026 |
| Country: US | FDA, National Drug Code | Identifier(s): 0703-4636 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
